Comparative Pharmacology
Head-to-head clinical analysis: NEXPLANON versus NIKKI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXPLANON versus NIKKI.
NEXPLANON vs NIKKI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Category C
Category C
Contraceptive
Contraceptive